TY - JOUR
T1 - Chromosome 14q32.2 Imprinted Region Disruption as an Alternative Molecular Diagnosis of Silver-Russell Syndrome
AU - Geoffron, Sophie
AU - Abi Habib, Walid
AU - Chantot-Bastaraud, Sandra
AU - Dubern, Béatrice
AU - Steunou, Virginie
AU - Azzi, Salah
AU - Afenjar, Alexandra
AU - Busa, Tiffanny
AU - Pinheiro Canton, Ana
AU - Chalouhi, Christel
AU - Dufourg, Marie Noëlle
AU - Esteva, Blandine
AU - Fradin, Mélanie
AU - Geneviève, David
AU - Heide, Solveig
AU - Isidor, Bertrand
AU - Linglart, Agnès
AU - Morice Picard, Fanny
AU - Naud-Saudreau, Catherine
AU - Oliver Petit, Isabelle
AU - Philip, Nicole
AU - Pienkowski, Catherine
AU - Rio, Marlène
AU - Rossignol, Sylvie
AU - Tauber, Maithé
AU - Thevenon, Julien
AU - Vu-Hong, Thuy Ai
AU - Harbison, Madeleine D.
AU - Salem, Jennifer
AU - Brioude, Frédéric
AU - Netchine, Irène
AU - Giabicani, Eloïse
N1 - Funding Information:
A.P.C. was supported by CNPq under grant no. 233262/2014-8. F.B. was supported by a Novo Nordisk “Growth Hormone, Growth and Metabolism” grant. F.B. and I.N. are members of the European Congenital Imprinting Disorders Network European Cooperation in Science and Technology (BM1208).
Funding Information:
Financial Support: This work was supported by the Institut National de la Santé et de la Recherche Médicale (INSERM) and funding from the Université Pierre et Marie Curie (UPMC-Paris VI). W.A.H. was supported by the People Programme Marie Curie Actions (MCA) of the European Union’s Seventh Framework Programme FP7/ITN Ingenium 2007–2013 under REA grant agreement no. 290123 and by the Société Française d’Endocrinologie et Diabétologie Pédiatrique.
Publisher Copyright:
Copyright © 2018 Endocrine Society.
PY - 2018/7/1
Y1 - 2018/7/1
N2 - Context Silver-Russell syndrome (SRS) (mainly secondary to 11p15 molecular disruption) and Temple syndrome (TS) (secondary to 14q32.2 molecular disruption) are imprinting disorders with phenotypic (prenatal and postnatal growth retardation, early feeding difficulties) and molecular overlap. Objective To describe the clinical overlap between SRS and TS and extensively study the molecular aspects of TS. Patients We retrospectively collected data on 28 patients with disruption of the 14q32.2 imprinted region, identified in our center, and performed extensive molecular analysis. Results Seventeen (60.7%) patients showed loss of methylation of the MEG3/DLK1 intergenic differentially methylated region by epimutation. Eight (28.6%) patients had maternal uniparental disomy of chromosome 14 and three (10.7%) had a paternal deletion in 14q32.2. Most patients (72.7%) had a Netchine-Harbison SRS clinical scoring system ≥4/6, and consistent with a clinical diagnosis of SRS. The mean age at puberty onset was 7.2 years in girls and 9.6 years in boys; 37.5% had premature pubarche. The body mass index of all patients increased before pubarche and/or the onset of puberty. Multilocus analysis identified multiple methylation defects in 58.8% of patients. We identified four potentially damaging genetic variants in genes encoding proteins involved in the establishment or maintenance of DNA methylation. Conclusions Most patients with 14q32.2 disruption fulfill the criteria for a clinical diagnosis of SRS. These clinical data suggest similar management of patients with TS and SRS, with special attention to their young age at the onset of puberty and early increase of body mass index.
AB - Context Silver-Russell syndrome (SRS) (mainly secondary to 11p15 molecular disruption) and Temple syndrome (TS) (secondary to 14q32.2 molecular disruption) are imprinting disorders with phenotypic (prenatal and postnatal growth retardation, early feeding difficulties) and molecular overlap. Objective To describe the clinical overlap between SRS and TS and extensively study the molecular aspects of TS. Patients We retrospectively collected data on 28 patients with disruption of the 14q32.2 imprinted region, identified in our center, and performed extensive molecular analysis. Results Seventeen (60.7%) patients showed loss of methylation of the MEG3/DLK1 intergenic differentially methylated region by epimutation. Eight (28.6%) patients had maternal uniparental disomy of chromosome 14 and three (10.7%) had a paternal deletion in 14q32.2. Most patients (72.7%) had a Netchine-Harbison SRS clinical scoring system ≥4/6, and consistent with a clinical diagnosis of SRS. The mean age at puberty onset was 7.2 years in girls and 9.6 years in boys; 37.5% had premature pubarche. The body mass index of all patients increased before pubarche and/or the onset of puberty. Multilocus analysis identified multiple methylation defects in 58.8% of patients. We identified four potentially damaging genetic variants in genes encoding proteins involved in the establishment or maintenance of DNA methylation. Conclusions Most patients with 14q32.2 disruption fulfill the criteria for a clinical diagnosis of SRS. These clinical data suggest similar management of patients with TS and SRS, with special attention to their young age at the onset of puberty and early increase of body mass index.
UR - http://www.scopus.com/inward/record.url?scp=85050162946&partnerID=8YFLogxK
U2 - 10.1210/jc.2017-02152
DO - 10.1210/jc.2017-02152
M3 - Article
C2 - 29659920
AN - SCOPUS:85050162946
SN - 0021-972X
VL - 103
SP - 2436
EP - 2446
JO - Journal of Clinical Endocrinology and Metabolism
JF - Journal of Clinical Endocrinology and Metabolism
IS - 7
ER -